Corvus Pharmaceuticals Inc Dossier - Source-backed chat

Corvus Pharmaceuticals Inc

CRVSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.92

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.93Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $919.4M

Enterprise Value $901.4M

Shares Outstanding 94.4M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK (interleukin-2-inducible T cell kinase) inhibition as a novel approach to immunotherapy. The company's lead asset, soquelitinib (CPI-818), is a selective, oral, small molecule ITK inhibitor with pipeline-in-a-product potential. It is currently being evaluated in a registration Phase 3 trial for relapsed/refractory peripheral T-cell lymphoma (PTCL) and a Phase 2 trial for moderate-to-severe atopic dermatitis. Backed by a major $189.4 million net financing completed in January 2026, Corvus has extended its cash runway into the second quarter of 2028, providing a highly secure financial foundation through multiple pivotal clinical readouts. The unique mechanism of action of ITK inhibition—which acts upstream to rebalance the immune system rather than broadly suppressing it—offers a highly differentiated therapeutic profile with potential for drug-free remissions in autoimmune and allergic diseases.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$27.00

Mean target$33.14

High · most bullish analyst$42.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

The Phase 3 PTCL trial fails to show a statistically significant PFS benefit over standard chemotherapies, or safety concerns emerge, delaying or halting the oncology program. Additionally, the Phase 2 atopic dermatitis trial yields ambiguous efficacy or fails to outperform placebo, undermining the therapeutic thesis of ITK inhibition. The company is forced to rely on early-stage pipeline assets, and the valuation contracts sharply toward its cash floor.

Base CaseCentral scenario

$33.1450%

Matches the consensus mean

Soquelitinib meets its primary endpoints in the Phase 3 PTCL trial, showing clinically meaningful PFS improvements and securing FDA approval as a niche oncology therapy. The Phase 2 atopic dermatitis trial demonstrates competitive efficacy and excellent tolerability, validating the ITK inhibition platform and supporting progression into Phase 3. Cash reserves remain robust, funding operations through key readouts into 2028, and the stock trades in line with consensus analyst valuations.

Bull CaseUpside scenario

$42.0030%

Soquelitinib achieves outstanding efficacy in the Phase 3 PTCL trial, demonstrating superior progression-free survival (PFS) compared to standard chemotherapies, leading to rapid FDA approval. Concurrently, the Phase 2 atopic dermatitis trial confirms high EASI-75 response rates (75%+) with a clean safety profile, positioning soquelitinib as a blockbuster oral alternative to injectable biologics. Geographic expansion via Angel Pharmaceuticals in China accelerates global commercialization, and the stock rerates toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly secure balance sheet with $236.7 million in cash and marketable securities as of March 31, 2026, providing a runway into Q2 2028.
Lead asset soquelitinib has a unique, upstream mechanism of action (ITK inhibition) that rebalances the immune system, offering pipeline-in-a-product potential across oncology, inflammatory, and allergic diseases.
Pivotal Phase 3 registration trial in relapsed/refractory PTCL is underway with a key data readout expected in late 2026.
Encouraging Phase 1 data in atopic dermatitis demonstrated dose-dependent efficacy (up to 75% EASI-75 response) and biomarker evidence of drug-free remissions.
Strong geographic and clinical leverage through collaboration partner Angel Pharmaceuticals in China, backed by a recent $13.5 million financing round.

Key Investment Risks

High concentration risk, as the company's valuation is heavily reliant on the clinical success of a single primary candidate, soquelitinib.
Clinical development risk inherent to clinical-stage biopharmaceuticals, with pivotal Phase 3 PTCL and Phase 2 atopic dermatitis trials subject to potential efficacy or safety setbacks.
Rising operating expenses as clinical trials scale, which could accelerate cash burn if development timelines are extended.
Intense competition in the immunology and oncology spaces from established pharmaceutical companies with significantly greater commercial and financial resources.

Thesis Invalidation Triggers

Failure of soquelitinib to meet the primary endpoint of progression-free survival (PFS) in the registration Phase 3 PTCL trial.
Emergence of severe or serious adverse events in the Phase 2 atopic dermatitis trial that compromise soquelitinib's safety and tolerability profile.
Inability to maintain clinical trial enrollment timelines for the PTCL or atopic dermatitis programs.
Termination or material negative restructuring of the collaboration agreement with Angel Pharmaceuticals in China.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.